Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Shanghai Zhaohui Pharmaceutical Company Limited, has received acceptance for its drug registration application for Polyethylene Glycol (3350) Electrolytes Powder by the National Medical Products Administration. This drug is intended for treating chronic constipation and represents a significant investment in research and development by the company, totaling approximately RMB6.21 million. The acceptance of this application could enhance Fosun Pharma’s market positioning in the pharmaceutical industry, particularly in China, where the demand for such treatments is growing.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating within the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, with a market focus on both domestic and international healthcare sectors.
Average Trading Volume: 8,192,263
Technical Sentiment Signal: Buy
Current Market Cap: HK$79.56B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.